View Older Stories View More Recent Stories
-
Roth Capital Starts Super Micro Computer (SMCI) at Buy
-
Roth Capital Downgrades AcelRx Pharmaceuticals (ACRX) to Neutral
-
Roth 'Encouraged' by Rexahn's (RNN) RX-3117 Receiving FDA Orphan Drug Designation; Offers Commentary
-
Roth Comments on ImmunoCellular's (IMUC) Licensing Agreement with Caltech; Affirms at 'Buy'
-
Roth Positive on SolarCity (SCTY) Following Closure of Silevo Deal; Affirms 'Buy' Rating
-
Roth Comments on TG Therapeutics' (TGTX) TGR-1202 Licensing Announcement
-
Roth Capital Downgrades Concur Technologies (CNQR) to Neutral
-
Roth Capital Starts Bluebird Bio (BLUE) at Buy
-
Sky Solar Holdings, Ltd. (SKYS) Files $100M IPO
-
Roth Capital Starts Ideal Power (IPWR) at Buy
-
Roth Capital Starts CymaBay Therapeutic (CBAY) at Buy
-
Roth 'Encouraged' by Spectrum's (SPPI) Licensing Agreement with CASI Pharma (CASI)
-
Streetinsider.com's Hot Lunchtime Reads 9/17: (ATVI) (NKE) (AAPL) (BLRX)
-
Preclinical BioLineRx (BLRX) BL-8040 Data on AML is Encouraging - Roth Capital
-
Roth Comments on Concert's (CNCE) Initiation of CTP-730 Phase 1
-
Roth Comments on ImmunoCellular (IMUC) Following ICT-107 Updates; Affirms 'Buy' Rating
-
Roth Sees 'Significant' and 'Impressive' Cost Efficiencies in TG Therapeutics' (TGTX) CLL Combo Phase 3
-
Roth Keeps Concert Pharma (CNCE) at 'Buy'; AVP-923 Phase 2 Data is Encouraging (AVNR)
-
Roth Commments on TG Therapeutics (TGTX); FDA Grants TG-1101 SPA in CLL Patients
-
Inventure Foods Announces Pricing of Public Offering by Selling Stockholder
-
Notable 52-Week Highs and Lows of the Day 9/11: (PANW) (LE) (MTN) High; (DLIW) (EOPN) (XNY) Low
-
Notable Analyst Rating Changes 9/11: (VRA) (WCC) (AAWW) Upgraded; (M) (EOPN) (ESRX) Downgraded
-
Roth Capital Starts Palo Alto Networks (PANW) at Buy
-
Roth Keeps Ligand (LGND) at 'Buy' Following New Captisol-Based Tech Launch
-
Roth Capital Starts Good Times Restaurants (GTIM) at Buy
-
Key Items for SolarCity (SCTY) Following Vivint Solar (VSLR) IPO Filing
-
Roth Raises PT on Keryx Biophama (KERX) to $32 Following Ferric Citrate Approval
-
Roth Capital Starts Cherokee Inc. (CHKE) at Buy
-
Roth Comments on China Solar Following Release of China's Updated NEA Policy for DG Solar (CSIQ) (JASO) (JKS) (TSL)
-
Inventure Foods (SNAK) Announces 3.3M Common Secodary Offering
-
Inventure Foods Announces Commencement of Public Offering by Selling Stockholder
-
Infinity (INFI) News a Positive for TG Therapeutics (TGTX) - Roth Capital
-
Roth Remains Positive on BioLineRx (BLRX); Dosing of BL-8040 Phase 1 Initiated
-
Roth Lifts Price Target on Regeneron (REGN) to $422 Following ODYSSEY Phase III Updates
-
Motorcar Parts of America (MPAA) Closes 2.4M Common Offering
-
Roth Positive on Trina Solar (TSL) Following Yunnan Metallurgical New Energy Transaction
-
Full FDA Approval of Keryx's (KERX) Zerenex Expected - Roth Capital
-
EZchip Semiconductor (EZCH) Pulls Out of Two Analyst Events
-
Interferon Therapy for HCV Still Expected Strong Amid Daklinza Approval - Roth (LGND) (BMY)
-
MEDIGUS ANNOUNCES COMPLETION OF $11.1 MILLION PRIVATE PLACEMENT
-
Roth Cuts PT, Makes Adjusts to Yingli Green Energy (YGE) Following Q2 Results, Outlook
-
Roth Comments on Ligand (LGND) Following Approval of Promact sNDA (GSK)
-
Roth Maintains Trina Solar (TSL) at 'Buy'; Light Q3 Outlook Will Hamper Stock, China Rebound Expected
-
Motorcar Parts of America (MPAA) Prices Larger 2.4M Common Offering at $26/Share
-
Pre-Open Stock Movers 8/25: (ITMN) (THI) (BKW) (LTM) Higher; (RGDO) (QIHU) (THOR) Lower (more...)
-
UPDATE: Roth Capital Starts Bio Blast Pharma (ORPN) at Buy
-
Roth Capital Starts xG Technology, Inc. (XGTI) at Buy
-
Roth Capital Comments on BioLineRx (BLRX) Following NoA for BL-7010; Sees Additional Milestones Approaching
-
Roth Capital Comments on Buy-Rated Galena (GALE) Following CEO Transition
-
Roth Affirms JA Solar (JASO) at 'Buy' Following Q2 Results, Outlook; Still has Attractive Valuation, Opportunities
